Literature DB >> 632082

Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma.

I J Fidler, G L Nicolson.   

Abstract

The organ distribution, arrest and survival of [125I]5-iodo-2'-deoxyuridine-labeled B16 melanoma cells with low (B16-F1) or high (B16-F10) metastatic potential were studied in a variety of normal and immunosuppressed syngeneic C57BL/6 mice, allogeneic A mice, and athymic nude NIH Swiss mice and their immunocompetent littermates. In addition, the in vitro aggregation properties of these tumor cells with various host organ cells in suspension were examined. Tumor cell arrest and survival following i.v. injection occurred at significantly higher rates in normal mice than in immune-depressed animals irrespective of strain, and, two weeks later, significantly more tumor colonies were found in the normal animals. In syngeneic or allogeneic animals, B16-F10 cells were arrested, survived and formed significantly more gross pulmonary tumors than B16-F1 cells. B16-F10 cells also aggregated in vitro with purified organ cells in suspension obtained from either syngeneic or allogeneic mice at a greater rate than B16-F1 cells. These results indicate that although host properties can affect the arrest and survival of circulating tumor emboli, they do not diminish or abolish the biological differences between the high and low metastatic variant B16 lines.

Entities:  

Mesh:

Year:  1978        PMID: 632082

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  7 in total

1.  125IUDR labelling efficiency and cytotoxicity for murine tumours in vivo and in vitro.

Authors:  B Hagmar; W Ryd
Journal:  Eur J Nucl Med       Date:  1982

2.  N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Jianming Yu; Michael A Ihnat; Jessica E Thorpe; Lora C Bailey-Downs
Journal:  Bioorg Med Chem       Date:  2013-01-10       Impact factor: 3.641

Review 3.  Inhibition of the arrest of hematogenously disseminated tumor cells.

Authors:  E Tsubura; T Yamashita; S Sone
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

4.  In vitro and in vivo adherence of tumor cell variants correlated with tumor formation.

Authors:  J Varani; E J Lovett; S Elgebaly; J Lundy; P A Ward
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

5.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

6.  Pyrostegia venusta heptane extract containing saturated aliphatic hydrocarbons induces apoptosis on B16F10-Nex2 melanoma cells and displays antitumor activity in vivo.

Authors:  Carlos R Figueiredo; Alisson L Matsuo; Felipe V Pereira; Aline N Rabaça; Camyla F Farias; Nátalia Girola; Mariana H Massaoka; Ricardo A Azevedo; Jorge A B Scutti; Denise C Arruda; Luciana P Silva; Elaine G Rodrigues; João Henrique G Lago; Luiz R Travassos; Regildo M G Silva
Journal:  Pharmacogn Mag       Date:  2014-04       Impact factor: 1.085

7.  Inhibition of melanocortin 1 receptor slows melanoma growth, reduces tumor heterogeneity and increases survival.

Authors:  Rita G Kansal; Matthew S McCravy; Jacob H Basham; Joshua A Earl; Stacy L McMurray; Chelsey J Starner; Michael A Whitt; Lorraine M Albritton
Journal:  Oncotarget       Date:  2016-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.